Communiqués Calithera Biosciences, Inc.

Actions

CALA

US13089P5070

Produits pharmaceutiques

Temps Différé OTC Markets 15:30:01 14/09/2026			Varia. 5j.	Varia. 1 janv.
0,000300 ^USD	+200,00%		-25,00%	+200,00%

14/06/23	Calithera Biosciences, Inc. lance le système Cala kIQ, proposant un soulagement significatif des tremblements pour les patients atteints de tremblements essentiels et maintenant de la maladie de Parkinson.	CI
31/03/23	Calithera Biosciences, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2022	CI

Communiqués

25/01/23	CALITHERA BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
09/01/23	CALITHERA BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
09/01/23	Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution	AQ
15/11/22	Calithera: Q3 Earnings Snapshot	AQ
14/11/22	CALITHERA BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
14/11/22	Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update	AQ
08/11/22	Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022	AQ
03/10/22	Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer	AQ
29/09/22	CALITHERA BIOSCIENCES, INC. : Termination of a Material Definitive Agreement (form 8-K)	AQ
29/09/22	Calithera Biosciences : Termination of Material Agreement - Form 8-K	PU
06/09/22	Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference	AQ
16/08/22	Calithera: Q2 Earnings Snapshot	AQ
16/08/22	CALITHERA BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
15/08/22	Calithera Biosciences : Reports Second Quarter 2022 Financial Results and Recent Highlights - Form 8-K	PU
15/08/22	Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights	AQ
08/08/22	Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022	AQ
14/07/22	Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences	AQ
13/07/22	Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences	AQ
06/07/22	Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer	AQ
23/06/22	Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma	AQ
14/06/22	CALITHERA BIOSCIENCES, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
14/06/22	Calithera Biosciences Announces 1-for-20 Reverse Stock Split	AQ
03/06/22	CALITHERA BIOSCIENCES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
23/05/22	CALITHERA BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
18/05/22	Calithera Biosciences to Present at the H.C. Wainwright Global Investment Conference	AQ